Ultimovacs is a clinical stage biotech company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase.
Ultimovacs was established in 2011. The company and its proprietary technology are based on pre-clinical and clinical research on immunotherapies conducted at the Oslo University Hospital. The company is a limited public liability company listed on the Oslo Stock Exchange in Norway.
Ultimovacs is headquartered at the Oslo Cancer Cluster Innovation Park in Oslo, Norway, and also has an office in Uppsala, Sweden. Ultimovacs is an active member of Oslo Cancer Cluster.
Ultimovacs seeks to become a leader in developing novel immunotherapeutic vaccines to treat a broad range of cancers. Ultimovacs’ lead universal cancer vaccine candidate UV1 is directed against human telomerase (hTERT), an antigen which is present in 85-90% of cancers in all stages of tumor growth. UV1 induces CD4 helper T cells which have the potential to provide inflammatory signals and T cell support believed to be critical for triggering a strong anti-tumor immune response. A broad clinical program, with Phase II trials in five cancer indications enrolling more than 670 patients, aims to demonstrate UV1’s impact in combination with other immunotherapies in multiple cancer types expressing telomerase and where patients have unmet medical needs. UV1 is universal, off-the-shelf and easy to use, and is a patented technology owned by Ultimovacs.
In addition, Ultimovacs’ adjuvant platform, based on the proprietary Tetanus-Epitope-Targeting (TET) technology, combines tumor-specific peptides and adjuvant in the same molecule. This next-generation vaccine technology has the potential to generate multiple vaccine candidates designed to achieve increased T cell responses to a broad range of target antigens. The first agent from this program is in Phase I clinical development.
For more information, download our company presentation from the Presentations and Publications page.
For patients
Ultimovacs is developing a new type of cancer treatment. We are currently evaluating the safety and efficacy. We have not secured regulatory approval and so we are not able to use the treatment outside of our clinical trial program.
If you are a cancer patient and wish to participate in a clinical trial, you should discuss this with the physician responsible for your treatment.